About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Biomarkers of Social Sensitivity in Major Depression

Biomarkers of Social Sensitivity in Major Depression

NCT02214511·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Institut National de la Santé Et de la Recherche Médicale, France

Age

18–60

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

For everybody :
benefit social health insurance
french speaker and reader
can stop smoking one day
volunteer to participate
For 1st group :
actual MDD diagnosed by a psychiatrist and meet the DSM IV criterias of MDD
no antidepressant treatment or antidepressant treatment for less than 7 days.

You may not be if

BMI \> 40
weekly sport \> 3 hours
pregnancy
fever or other infection symptoms during the last month
significant or unstable disease, especially neurologic or inflammatory.
recent history of coronary disease, ulcer, COPD, severe dyslipemia, kidney or liver failure.
severe smoking addiction (fagerström \> 8)
antiinflammatory or immunomodulatory treatment during last month
For 1st group :
no psychiatric treatment except benzodiazepin if no severe vigilance trouble and antidepressant treatment more than 7 days
subjects under legal protection
constraint hospitalization
significant suicidal risk
resistant MDD
psychiatric comorbidity
For 2nd group :
\- psychiatric disease, actual or past according to DSM IV criterias

The record

StatusCompleted

PhaseNo phase

Taking part50

StartedOct 2014

UpdatedAug 30, 2021

Conditions

Major Depressive Disorder

Where1

ICM, Pitié Salpêtrière Hospital
Paris, France